<DOC>
	<DOCNO>NCT02906930</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy safety oral semaglutide versus placebo subject type 2 diabetes mellitus treat diet exercise .</brief_summary>
	<brief_title>Efficacy Safety Oral Semaglutide Versus Placebo Subjects With Type 2 Diabetes Mellitus Treated With Diet Exercise Only</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age equal 18 year time signing inform consent.For Japan : Male female , age equal 20 year time signing informed consent . For Algeria : Male female , age equal 19 year time signing informed consent Diagnosed type 2 diabetes mellitus least 30 day prior day screen HbA1c ( glycosylated haemoglobin ) 7.09.5 % ( 5380 mmol/mol ) ( inclusive ) Treatment diet exercise least 30 day prior day screen Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) For Japan : Adequate contraceptive measure abstinence ( sex ) , diaphragm , condom ( partner ) , intrauterine device , sponge , spermicide oral contraceptives.For Czech Republic : Adequate contraceptive measure always one highly reliable method ( intrauterine device , sterilisation one partner , hormonal birth control method ) plus one supplementary barrier method ( condom , diaphragm ) spermicide . In justified case , combination may replace doublebarrier method spermicide . Total sexual abstinence may also consider contraception . ( Please note : hormonal contraception always discuss gynaecologist ) Any disorder , investigator 's opinion might jeopardise subject 's safety compliance protocol Family personal history multiple endocrine neoplasia type 2 medullary thyroid carcinoma History pancreatitis ( acute chronic ) History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) Any follow : myocardial infarction , stroke hospitalisation unstable angina transient ischaemic attack within past 180 day prior day screen randomisation Subjects presently classify New York Heart Association Class IV . Planned coronary , carotid peripheral artery revascularisation know day screen Subjects alanine aminotransferase 2.5 x upper normal limit Renal impairment define estimate glomerular filtration rate 60 mL/min/1.73 m^2 per Chronic Kidney Disease Epidemiology Collaboration formula Treatment medication indication diabetes obesity period 90 day day screen . An exception shortterm insulin treatment acute illness total equal 14 day Proliferative retinopathy maculopathy require acute treatment . Verified fundus photography dilate fundoscopy perform within 90 day prior randomisation History presence malignant neoplasm within last 5 year ( except basal squamous cell skin cancer insitu carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>